LEADER 01491nam  2200433   450 
001 9910698376703321
005 20221105114318.0
035   $a(CKB)3450000000002450
035   $a(NjHacI)993450000000002450
035   $a(OCoLC)173662201
035   $a(EXLCZ)993450000000002450
100   $a20221105d2007      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAntiretroviral (ARV) drug resistance in the developing world /$fPaul Shekelle [and ten others]
210  1$aRockville, Maryland :$cAgency for Healthcare Research and Quality (US),$d[2007]
210  4$dİ2007
215   $a1 online resource (212 pages)
225 1 $aEvidence report/technology assessment ;$vno. 156
225 1 $aAHRQ publication ;$vno. 07-E 014
300   $aTitle from title screen (viewed on Oct. 4, 2007).
300   $a"September 2007."
517   $aAntiretroviral
606   $aAntiretroviral agents
615  0$aAntiretroviral agents.
676   $a616.9792061
700   $aShekelle$b Paul
701   $aShekelle$b Paul G$01236354
712 02$aSouthern California Evidence-Based Practice Center/RAND.
712 02$aUnited States.$bAgency for Healthcare Research and Quality.
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910698376703321
996   $aAntiretroviral (ARV) drug resistance in the developing world$93545312
997   $aUNINA